Clinical Research, Pharma & Healthcare FinancingAkeso’s IL-4Rα/ST2 Antibody Cleared for Seven Phase II TrialsPR NewswireFebruary 11, 2026February 12, 2026 by PR NewswireFebruary 11, 2026February 12, 2026021 Akeso, Inc. (9926.HK) is pleased to announce that the National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139, a...